 | • レポートコード：MRC2303B130 • 出版社/出版日：Mordor Intelligence / 2023年3月 • レポート形態：英文、PDF、166ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医療 |
| Single User | ￥712,500 (USD4,750) | ▷ お問い合わせ |
| Corporate License | ￥1,312,500 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| モルドールインテリジェンス社の市場調査書では、2021年に2,177.16百万ドルであった世界の鎌状赤血球症治療市場規模が、予測期間中（2022～2027年）に年平均17.31％上昇すると推測されています。本調査書では、鎌状赤血球症治療の世界市場を広く調査・分析をし、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、治療モダリティ別（輸血、骨髄移植、薬物療法）分析、エンドユーザー別（病院、専門クリニック、その他）分析、地域別（アメリカ、カナダ、メキシコ、ドイツ、イギリス、フランス、イタリア、スペイン、中国、日本、インド、オーストラリア、韓国、中東、南アフリカ、ブラジル、アルゼンチン）分析、競争状況、市場機会・将来動向などを整理しています。また、本書には、Novartis AG、Global Blood Therapeutics Inc.、Emmaus Medical Inc.、Addmedica、Medunik USA、Bristol Myers Squibb Co.、Sanofi SA、Bluebird Biotechnology、Pfizer Inc.、Aruvant Sciences Inc.、Glycomimetics Inc.、Editas Medicine Inc.、CRISPR Therapeuticなどの企業情報が含まれています。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・世界の鎌状赤血球症治療市場規模：治療モダリティ別 - 輸血の市場規模 - 骨髄移植の市場規模 - 薬物療法の市場規模 ・世界の鎌状赤血球症治療市場規模：エンドユーザー別 - 病院における市場規模 - 専門クリニックにおける市場規模 - その他エンドユーザーにおける市場規模 ・世界の鎌状赤血球症治療市場規模：地域別 - 北米の鎌状赤血球症治療市場規模 アメリカの鎌状赤血球症治療市場規模 カナダの鎌状赤血球症治療市場規模 メキシコの鎌状赤血球症治療市場規模 … - ヨーロッパの鎌状赤血球症治療市場規模 ドイツの鎌状赤血球症治療市場規模 イギリスの鎌状赤血球症治療市場規模 フランスの鎌状赤血球症治療市場規模 … - アジア太平洋の鎌状赤血球症治療市場規模 中国の鎌状赤血球症治療市場規模 日本の鎌状赤血球症治療市場規模 インドの鎌状赤血球症治療市場規模 … - 南米/中東の鎌状赤血球症治療市場規模 南アフリカの鎌状赤血球症治療市場規模 ブラジルの鎌状赤血球症治療市場規模 アルゼンチンの鎌状赤血球症治療市場規模 … ・競争状況 ・市場機会・将来動向 |
The sickle cell treatment market was valued at USD 2,177.16 million in 2021, registering a CAGR of 17.31% during the forecast period, 2022-2027.
The implication of the COVID-19 pandemic in the healthcare industry is profound. With the rapid increase in patient numbers, healthcare facilities and providers’ burden are also increasing. Many hospitals decided to postpone and cancel surgeries. The sickle cell treatment market witnessed the mixed impact of the pandemic. The pandemic has squeezed the demand and donor base of blood supplies. Lockdown and travel restrictions resulted in a decline in the number of donors and the cancellation of numerous drives across the globe. According to United States Blood Centers, blood drive schedules had declined in 2019, leading to about 250,000 missed blood donations. Furthermore, according to American Red Cross Blood Services, more than 50,000 blood drives were canceled or moved due to the pandemic in March 2020. As a result, the demand for blood transfusions and bone marrow transplants decreased. However, pharmaceutical firms reported positive growth in 2020 despite supply disruption and new regulatory approvals.
The major driving factor for the growth of the sickle cell treatment market is the increasing prevalence of sickle cell disease. Sickle cell disease (SCD) affects millions of people worldwide, with a high prevalence among those with ancestors from Sub-Saharan Africa, Spanish-speaking regions of the Western Hemisphere (South America, the Caribbean, and Central America), Saudi Arabia, India, and the Mediterranean countries such as Turkey, Greece, and Italy. According to the Centers for Disease and Prevention Control, 2020, SCD affects approximately 100,000 Americans. Similarly, according to the National Health Institute, United States, 2020, nearly 90 % of the world’s SCD population lives in three countries: Nigeria, India, and the Democratic Republic of Congo, where the disease affects up to 2% of the population, and the carrier prevalence rate (sickle cell trait) is as high as 10 to 30%. Additionally, increasing research and development activity, a solid pipeline, and an expanding patient pool are all predicted to have an impact on market growth. For example, in December 2021, the United States Food and Drug Administration granted accelerated approval to Oxbryta (Voxelotor) for the treatment of sickle cell disease (SCD) in adults and pediatric patients 12 years of age and older. According to the World Health Organization 2020, approximately 5% of the global population carries trait genes for hemoglobin disorders, primarily sickle cell disease and thalassemia. Hemoglobin disorders are genetic blood diseases caused by the inheritance of mutant hemoglobin genes from both parents, who are generally healthy. Every year, over 300,000 babies are born with severe hemoglobin disorders. Through management and prevention programs, the health burden of hemoglobin disorders can be effectively reduced.
Product approvals are another factor in the growth of the market. For instance, in October 2020, Novartis received the European Commission’s approval for the drug Adakveo (crizanlizumab) for pain crises in patients with SCD. It is the first targeted sickle cell disease therapy for the reduction and prevention of SCD complications.
However, the high cost of the treatment is restraining the growth of the market studied.
Sickle Cell Treatment Market Trends
The Blood Transfusion Segment is Expected to Witness High Growth over the Forecast Period
The blood transfusion segment is expected to witness healthy growth over the forecast period. The growth of this segment is attributed to the high demand for blood transfusion in sickle cell treatment and the increase in the prevalence of SCD. Blood transfusions enable the supply of normal red blood cells, which can enhance hemoglobin levels to improve oxygen delivery in the body, thereby reducing sickle cell blockage in blood vessels and minimizing the desire to make more sickle cells. As per the American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support remains a key intervention in the management of patients with sickle cell disease (SCD). Red cell transfusions are used in the acute and chronic management of many complications related to SCD.
According to the report published in the HINDAWI journal, September 2020, titled “Current modalities of sickle cell disease management”, there is an increasing interest in the role of transfusion therapy in the management of SCD,with an estimation that over 50.0% of SCD children would have received at least one or more blood transfusions in their pediatric lifetime.
Additionally, the opportunities for players in this domain lie in plasma transfusion. According to Clinicaltrials.gov (2020), a series of plasma transfusion trials are underway for sickle cell treatment in the United States. For instance, in December 2021, a study was published titled “Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of FTX-6058” for a Phase 1 multicenter, open-label study evaluating the safety, tolerability, pharmacokinetics (PK), fetal hemoglobin (HbF) induction and biological activity of FTX-6058 in subjects 18-65 years of age with sickle cell disease (SCD). Thus, the blood transfusion market is expected to witness rapid growth during the forecast period
North America is Expected to Dominate the Sickle Cell Treatment Market During the Forecast Period
Geographically, North America dominates the overall sickle cell treatment market, with the United States being the major contributor to the market. The growth in the region is attributed to improving access to SCD treatment and potential pipeline candidates. The strong government support in the United States will further foster the healthy development of the market. For instance, according to the report published in National Centers for Biotechnological Information, in 2020, National Heart, Lung, and Blood Institute (NHLBI) launched the Cure Sickle Cell Initiative, a collaborative research effort that will accelerate the development of genetic therapies to cure SCD.
Similarly, the presence of a strong key market player with a strong pipeline aids in the market growth in the region. For instance, Global Blood Therapeutics in the United States has a strong pipeline in the different phases of clinical trials such as Voxelotor (Phase IV), Voxelotor hope-kids1(Phase IV), Inclacumab (Phase II), GBT021601 (Phase II), Hbf Inducer, Anti- sicking, Inflammation and Oxidative Stress Reduction, etc. These drugs are expected to be launched during the forecast period. Moreover, Food and Drug Administration (FDA), in November 2019, approved the commercialization of Volexetor in the United States for the treatment of SCD.
Additionally, increasing births with SCD in America will increase the demand for sickle cell treatment. According to a report of the National Institute of Health published in the National Center of Biotechnology Information in 2021, sickle cell disease (SCD) is a multisystem disorder and the most common genetic disease in the United States, affecting 1 in 500 African Americans. Also, about 1 in 12 African Americans carry the autosomal recessive mutation, and approximately 300,000 infants are born with sickle cell anemia annually. Thus, the aforementioned factors together are expected to favor the growth of the studied market in the region.
Sickle Cell Treatment Market Competitor Analysis
The sickle cell treatment market is highly competitive with the presence of several regional and global companies. Companies are taking initiatives to develop novel therapies in the market studied. Some of the players in the market include Novartis AG, Global Blood Therapeutics Inc., Emmaus Medical Inc., Addmedica, Medunik USA Inc., and Bristol-Myers Squibb Company.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Prevalence of Sickle Cell Disease
4.2.2 Increasing Research and Development Activity
4.3 Market Restraints
4.3.1 High Cost of Treatments
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION (Market Size by Value – USD million)
5.1 By Treatment Modality
5.1.1 Blood Transfusion
5.1.2 Bone Marrow Transplant
5.1.3 Pharmacotherapy
5.2 By End User
5.2.1 Hospitals
5.2.2 Specialty Clinics
5.2.3 Other End Users
5.3 By Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East & Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East & Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Novartis AG
6.1.2 Global Blood Therapeutics Inc.
6.1.3 Emmaus Medical Inc.
6.1.4 Addmedica
6.1.5 Medunik USA
6.1.6 Bristol Myers Squibb Co.
6.1.7 Sanofi SA
6.1.8 Bluebird Biotechnology
6.1.9 Pfizer Inc.
6.1.10 Aruvant Sciences Inc.
6.1.11 Glycomimetics Inc.
6.1.12 Editas Medicine Inc.
6.1.13 CRISPR Therapeutic
7 MARKET OPPORTUNITIES AND FUTURE TRENDS